The concept of innovative drugs has rebounded, with InventisBio and InnoCare Pharma reaching historical highs
In the afternoon, the innovative drug concept showed signs of recovery, with InventisBio and InnoCare Pharma both rising over 6%, reaching historical highs. Yipinhong, New Horizon, BeiGene, Borui Pharmaceutical, and Kangchen Pharmaceutical all rose by more than 5%. On the news front, a research report from Huaxin Securities pointed out that in 2025, the National Healthcare Security Administration will add a new commercial insurance innovative drug catalog to support new drugs with high clinical value but payment bottlenecks. It is expected that products entering the commercial insurance catalog will receive a higher payment ratio, enhancing the accessibility of new drugs
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments